Syndax Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Accounts Payable of -$11.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$5.97M, a 181.70% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$5.74M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $2.75M, a 59.07% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$3.53M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2025 was $4.95M, a 197.54% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.67M, a 70.33% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2023 was $5.61M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.32M, a 161.04% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$11.71M 10-Q · filed 2026-08-04 | -$8.95M derived: sum of 3 quarters · filed 2026-08-04 | -$12.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$5.74M 10-Q · filed 2026-04-30 | -$2.98M derived: sum of 2 quarters · filed 2026-04-30 | -$6.51M derived: sum of 3 quarters · filed 2026-04-30 | $796.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$773.00K derived: sum of 2 quarters · filed 2026-02-26 | $6.53M derived: sum of 3 quarters · filed 2026-08-04 | $4.95M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.78M derived: sum of 2 quarters · filed 2026-08-04 | $2.20M 10-Q · filed 2025-11-03 | $8.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $7.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.73M 10-Q · filed 2026-08-04 | $12.46M derived: sum of 3 quarters · filed 2026-08-04 | $5.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$1.58M 10-Q · filed 2026-04-30 | $5.15M derived: sum of 2 quarters · filed 2026-04-30 | -$1.52M derived: sum of 3 quarters · filed 2026-04-30 | $1.24M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $58.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.82M derived: sum of 3 quarters · filed 2026-02-26 | $1.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$6.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$3.91M derived: sum of 2 quarters · filed 2025-11-03 | -$5.06M 10-Q · filed 2025-11-03 | -$1.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $1.61M 10-Q · filed 2025-08-04 | $5.52M derived: sum of 3 quarters · filed 2026-02-26 | $589.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$1.15M 10-Q · filed 2025-05-05 | $2.76M derived: sum of 2 quarters · filed 2026-02-26 | -$2.17M derived: sum of 3 quarters · filed 2026-02-26 | $752.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.02M derived: sum of 2 quarters · filed 2026-02-26 | $1.90M derived: sum of 3 quarters · filed 2026-02-26 | $5.61M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$4.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$2.01M derived: sum of 2 quarters · filed 2024-11-05 | $1.70M 10-Q · filed 2024-11-05 | -$1.06M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $6.63M 10-Q · filed 2024-08-01 | $3.87M derived: sum of 3 quarters · filed 2025-03-03 | $4.54M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $3.71M 10-Q · filed 2024-05-08 | $943.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.62M derived: sum of 3 quarters · filed 2025-03-03 | -$174.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$2.09M derived: sum of 2 quarters · filed 2025-03-03 | -$3.88M derived: sum of 3 quarters · filed 2025-03-03 | -$1.32M 10-K · filed 2025-03-03 |
| 2022-09-30 | $676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$1.12M derived: sum of 2 quarters · filed 2023-11-02 | $1.45M 10-Q · filed 2023-11-02 | $1.99M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $769.00K 10-Q · filed 2023-08-03 | $1.32M derived: sum of 3 quarters · filed 2024-02-27 | $2.81M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $2.56M 10-Q · filed 2023-05-08 | $3.11M derived: sum of 2 quarters · filed 2024-02-27 | $4.61M derived: sum of 3 quarters · filed 2024-02-27 | $1.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $547.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.04M derived: sum of 2 quarters · filed 2024-02-27 | -$860.00K derived: sum of 3 quarters · filed 2024-02-27 | $2.16M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.41M derived: sum of 2 quarters · filed 2022-11-03 | $1.61M 10-Q · filed 2022-11-03 | $1.29M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $116.00K 10-Q · filed 2022-08-08 | -$212.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $3.02M 10-Q · filed 2022-05-09 | $2.69M derived: sum of 2 quarters · filed 2023-02-28 | $4.70M derived: sum of 3 quarters · filed 2023-02-28 | -$2.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.68M derived: sum of 2 quarters · filed 2023-02-28 | -$5.49M derived: sum of 3 quarters · filed 2023-02-28 | -$2.67M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$5.16M derived: sum of 2 quarters · filed 2021-11-15 | -$2.34M 10-Q · filed 2021-11-15 | -$2.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$7.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$4.35M 10-Q · filed 2021-08-09 | -$4.80M derived: sum of 3 quarters · filed 2022-03-01 | -$445.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $2.82M 10-Q · filed 2021-05-11 | $2.37M derived: sum of 2 quarters · filed 2022-03-01 | $6.72M derived: sum of 3 quarters · filed 2022-03-01 | $4.65M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.90M derived: sum of 2 quarters · filed 2022-03-01 | $1.83M derived: sum of 3 quarters · filed 2022-03-01 | $4.74M 10-K · filed 2022-03-01 |
| 2019-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.29M derived: sum of 2 quarters · filed 2020-11-05 | $5.19M 10-Q · filed 2020-11-05 | $3.45M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | -$2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $838.00K 10-Q · filed 2020-08-06 | -$902.00K derived: sum of 3 quarters · filed 2021-03-12 | -$3.02M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $2.91M 10-Q · filed 2020-05-07 | $1.17M derived: sum of 2 quarters · filed 2021-03-12 | -$951.00K derived: sum of 3 quarters · filed 2021-03-12 | $1.76M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$3.86M derived: sum of 2 quarters · filed 2021-03-12 | -$1.15M derived: sum of 3 quarters · filed 2021-03-12 | -$792.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | -$2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $590.00K derived: sum of 2 quarters · filed 2019-11-07 | $948.00K 10-Q · filed 2019-11-07 | $960.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $3.07M 10-Q · filed 2019-08-07 | $3.08M derived: sum of 3 quarters · filed 2020-03-05 | $2.07M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $358.00K 10-Q · filed 2019-05-08 | $370.00K derived: sum of 2 quarters · filed 2020-03-05 | -$636.00K derived: sum of 3 quarters · filed 2020-03-05 | -$202.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$994.00K derived: sum of 2 quarters · filed 2020-03-05 | -$560.00K derived: sum of 3 quarters · filed 2020-03-05 | -$194.00K 10-K · filed 2020-03-05 |
| 2017-09-30 | -$1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$572.00K derived: sum of 2 quarters · filed 2018-11-05 | -$206.00K 10-Q · filed 2018-11-05 | $159.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $434.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $800.00K 10-Q · filed 2018-08-08 | $1.17M derived: sum of 3 quarters · filed 2019-03-07 | $1.78M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $366.00K 10-Q · filed 2018-05-09 | $731.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.34M derived: sum of 3 quarters · filed 2019-03-07 | $1.69M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $977.00K derived: sum of 2 quarters · filed 2019-03-07 | $1.33M derived: sum of 3 quarters · filed 2019-03-07 | $923.00K 10-K · filed 2019-03-07 |
| 2016-09-30 | $612.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $961.00K derived: sum of 2 quarters · filed 2017-11-08 | $558.00K 10-Q · filed 2017-11-08 | $1.17M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $349.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$54.00K 10-Q · filed 2017-08-10 | $561.00K derived: sum of 3 quarters · filed 2018-03-08 | $641.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$403.00K 10-Q · filed 2017-05-09 | $212.00K derived: sum of 2 quarters · filed 2018-03-08 | $292.00K derived: sum of 3 quarters · filed 2018-03-08 | $64.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $695.00K derived: sum of 2 quarters · filed 2018-03-08 | $467.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.04M 10-K · filed 2018-03-08 |
| 2015-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$148.00K derived: sum of 2 quarters · filed 2016-11-14 | $430.00K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$228.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $350.00K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $578.00K 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | -$726.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |